Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first- line therapy in patients with advanced ovarian cancer

Journal of Clinical Oncology

Volumn 17, Issue 3, 1999, Pages 747-755

  Herben PhD, Virginie M M ^a   Nannan Panday, Vinodh R ^a   Richel, Dick J ^a   Schellens, Jan H M ^a   Van Der Vange, Nine ^a   Rosing, Hilde ^a   Beusenberg, Fred D ^a   Hearn, Solange ^a   Doyle, Edward ^a   Beijnen, Jos H ^a   Ten Bokkel Huinink, Wim W ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; FATIGUE; FEMALE; HUMAN; HYPOMAGNESEMIA; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

EID: 0345059451     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.3.747     Document Type: Article

References (32)

1. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
2. Hsiang Y-H, Liu LF, Wall ME, et al: DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogs. Cancer Res 49:4385-4389, 1989
3. Gordon A, Carmichael J, Malfetano J, et al: Final analysis of a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma: International Topotecan Study Group. Proc Am Soc Clin Oncol 17:356a, 1998 (abstr)
4. Swisher EM, Mutch DG, Rader JS, et al: Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol 66:480-486, 1997
5. Lilenbaum RC, Ratain MJ, Miller AA, et al: Phase I study of paclitaxel and topotecan in patients with advanced tumors: A Cancer and Leukemia Group B study. J Clin Oncol 13:2230-2237, 1995
6. O'Reilly S, Fleming GF, Baker SD, et al: Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: A Gynecologic Oncology Group study. J Clin Oncol 15:177-186, 1997
7. Miller AA, Hargis JB, Lilenbaum RC, et al: Phase I study of topotecan and cisplatin in patients with advanced solid tumors: A Cancer and Leukemia Group B study. J Clin Oncol 12:2743-2750, 1994
8. Rowinsky EK, Kaufmann SH, Baker SD, et al: Sequences of topotecan and cisplatin: Phase I, pharmacologic, and in vitro studies to examine sequence dependence. J Clin Oncol 14:3074-3084, 1996
9. Raymond E, Burris HA, Rowinsky EK, et al: Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma. Ann Oncol 8:1003-1008, 1997
10. Chou T-C, Motzer RJ, Tong Y, et al: Computer quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design. J Natl Cancer Inst 86:1517-1524, 1994
11. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31, 1976
12. National Cancer Institute: Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD, Division of Cancer Treatment, National Cancer Institute, 1988
13. World Health Organization: Handbook for Reporting Results of Cancer Treatment. WHO publication no. 48. Geneva, Switzerland, World Health Organization, 1979
14. Huizing MT, Keung AC, Rosing H, et al: Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11:2127-2135, 1993
15. Rosing H, Doyle E, Davies BE, et al: High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma. J Chromatogr B Biomed Appl 668:107-115, 1995
16. van Warmerdam LJC, Van Tellingen O, Maes RAA, et al: Validated method for the determination of carboplatin in biological fluids by Zeeman atomic absorption spectrometry. Fresenius J Anal Chem 351:1820-1824, 1995
17. Rowland M, Tozer TN: Clinical Pharmacokinetics: Concepts and Applications (ed 2). Philadelphia, PA, Lea and Febiger, 1989, pp 78-97
18. Cheng M-F, Chatterjee S, Berger NA: Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol Res 6:269-279, 1994
19. Ma J, Maliepaard M, Nooter K, et al: Synergistic toxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro. Cancer Chemother Pharmacol 41:307-316, 1998
20. Hochster H, Speyer J, Oratz R, et al: Phase I study of taxol with 14-day topotecan continuous low-dose infusion. Proc Am Soc Clin Oncol 14:486, 1995 (abstr)
21. Sarosy G, Kohn E, Stone DA, et al: Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 10:1165-1170, 1992
22. Saltz L, Sirott M, Young C, et al: Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst 85:1499-1507, 1993
23. Rowinsky EK, Grochow LB, Sartorius SE, et al: Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors. J Clin Oncol 14:1224-1235, 1996
24. Wiernik PH, Schwartz EL, Strauman JJ, et al: Phase I clinical and pharmacokinetic study of taxol. Cancer Res 47:2486-2493, 1987
25. Huizing MT, Giaccone G, van Warmerdam LJ, et al: Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer: A European Cancer Centre. J Clin Oncol 15:317-329, 1997
26. Herben VM, ten Bokkel Huinink WW, Beijnen JH: Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 31:85-102, 1996
27. van Warmerdam LJC, Verweij J, Rosing H, et al: Limited sampling models for topotecan pharmacokinetics. Ann Oncol 5:259-264, 1994
28. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 12:2654-2666, 1994
29. Connelly E, Markman M, Kennedy A, et al: Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: Unexpected incidence of neurotoxicity. Gynecol Oncol 62:166-168, 1996
30. Piccart MJ, Bertelsen K, Stuart G, et al: Is cisplatin-paclitaxel (P-T) the standard in first-line treatment of advanced ovarian cancer? The EORTC-GCCG, NOCOVA, NCI-C and Scottish intergroup experience. Proc Am Soc Clin Oncol 16:352a, 1997 (abstr)
31. Gore M, Rustin G, Calvert H, et al: A multicentre randomised phase III study of topotecan administered intravenously or orally for advanced epithelial ovarian carcinoma. Proc Am Soc Clin Oncol 17:349a, 1998 (abstr)
32. Markman M: Topotecan: An important new drug in the management of ovarian cancer. Semin Oncol 24:S5-S11, 1997